Value through Innovation05 July 2015

Our four major Research Areas

Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:

1. Discovery Research Therapeutic Areas where we build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.

2. Scientific platforms where we focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.

3. Research Beyond Borders where we explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.

Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit.

Our strategy focuses on four therapeutic research areas with high unmet medical need:

  • Immunology & Respiratory diseases,
  • Cardiometabolic diseases,
  • Central nervous system diseases, and
  • Oncology.

Our Key Research Areas

  • Cardiometabolic Diseases Research
    Cells of the pancreas of a diabetic (Copyright: Lennart Nilsson)

    Many years of experience in this therapeutic area have allowed us to help millions of patients affected by potentially life-threatening cardiovascular and metabolic diseases. Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes.

    Our current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic Steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity.

    Around 300 scientists work in our fully integrated drug discovery centre of excellence for Cardiometabolic research at sites in Biberach, Germany and Ridgefield, CT, USA. With extensive capabilities in both small molecules and biotherapeutics, they are working with many academic and corporate partners to discover new treatments to address continually evolving unmet medical needs.

    Specific opportunities for partnering in Disovery Research include:

    • Beta-cell degeneration/regeneration
    • Insulin resistance and adipose tissue inflammation
    • Gut microbiota
    • Novel approaches to treat obesity
    • Fibrotic processes in NASH and chronic kidney diseases
    • Pathogenesis of diabetic retinopathy
    • Translational aspects for all indications (i.e. predictive animal models, imaging etc.)

    If you have a research project and would like to explore opportunities to partner please contact our partnering team with more information. 

    To discover our recent publications in Cardiometabolic Research please visit our Scientific Publication Pages.

  • Central Nervous System Diseases Research
    Synapses: Contacts between nerve cells in humans (Copyright: Lennart Nilsson)

    Progressive degeneration of the nerve cells is typical for all chronic neurological diseases. Our scientists are investigating ways of identifying and developing new treatments which can intervene in the process. The aim is to provide patients and doctors with improved treatments to address the symptoms of these diseases, and to find ways of inhibiting the basic pathological processes, which are responsible for disease progression.

    Recently, we extended our research efforts into psychiatric diseases. We recognize that the current classification of psychiatric diseases does not reflect the underlying neurobiology. Therefore, our goal is to identify and analyse multiple psychiatric diseases.

    More than 200 scientists work at our fully integrated CNS drug discovery centre in Biberach, Germany. Using their own capabilities in both small molecules and biotherapeutics, and working together with their academic and corporate partners, their focus is on disease pathophysiology and genetics to drive pathway and target selection.

    Our Discovery Research focus is on:

    • Psychiatric indications – major symptoms domains i.e. cognitive impairment and negative symptoms associated with schizophrenia and underlying brain circuitry
    • Depression
    • Impulsivity
    • Alzheimer Disease
    • Parkinson Disease

    Specific opportunities for partnering in Discovery Research include:

    • Selective modulation of synaptic plasticity
    • Interference in neurodegenrative pathways
    • Behavioural tests and models for defined symptom domains
    • Circuit genetics
    If you have a research project and would like to explore opportunities to partner please contact our partnering team with more information.

     
     
    To discover our recent publications in CNS please visit our Scientific Publication Pages.

    News Topics

  • Immunology and Respiratory Research
    Micrograph of the lung mucosa (Copyright: Lennart Nilsson)

    Boehringer Ingelheim is one of the leading pharmaceutical companies worldwide in the treatment of respiratory diseases.

    It has been recognized that respiratory diseases such as COPD or Asthma are heterozygous syndromes that are often associated with an aberrant immune response of the afflicted patient. Therefore it made sense to create a new Discovery Research Therapeutic Area that combines our long-standing competence and success story in respiratory diseases with our expertise in immunology.

    Within this newly formed department, more than 200 scientists work in our fully integrated drug discovery centre of excellence for Immunology and Respiratory Diseases research at sites in Biberach, Germany and Ridgefield, CT, USA.
    With extensive capabilities in both small molecules and biotherapeutics, they are working with many academic and corporate partners to discover new treatments to address continually evolving unmet medical needs.

    Our Discovery Research focus is on:

    • Mucosal barrier injury
    • Tissue remodelling
    • Innate effector function
    • Immune modulation

    Specific opportunities for research partnering for respiratory and immunology include:

    A) Respiratory diseases

    • Steroid (resistance) insensitivity in severe asthma and COPD
    • Models to study mechanisms to resolve inflammation in the diseased lung
    • Animal models of exacerbation and smooth muscle proliferation
    • Mimicking smoke-induced pathology in vitro
    • Knock-down technologies in rodent lung
    • Mechanisms of acute lung injury
    • Prevention of asthma by immunomodulation/desensitisation
    • Access to human mast cells and lung tissue of asthmatics, IPF and COPD patients

    B) Immunology

    - Building deep expertise in core pathways and targets associated with disease-relevant processes: 

    • Adaptive immunity and co-stimulation (e.g. effector cells and autoantibodies)
    • Innate effector function (e.g. macropahages and dendritic cells)
    • Tissue regulation (e.g. epithelial-immune interactions)

    - Translational concepts that facilitate precision medicine 

    • Deep understanding and validation of molecular targets in disease
    • Access to samples from well-annotated patients cohorts

    If you have a research project and would like to explore opportunities to partner please contact our partnering team with more information.

    To discover our recent publications in Immunology & Respiratory please visit our Scientific Publication Pages for Immunology and Respiratory .
  • Oncology Research

    Opportunities for effective drug discovery in oncology have never been better. Blueprints of the genetic and biochemical workings of cancer cells allow scientists in our laboratories to focus on promising targets for potential new therapeutic approaches. The impact of modern cancer genetics and immunotherapy on drug discovery is already changing the practice of medicine in oncology, with both biopharmaceuticals and small-molecules contributing to a growing repertoire of therapies.

    Our fully integrated drug discovery centre in Vienna, Austria has more than 250 scientists with extensive capabilities in both small molecule and biotherapeutic discovery. A large number of collaborations with both academic partners and biotechnology companies are supporting our search for novel targets, biomarkers, drug candidates and treatment modalities.

    Our Discovery Research focus is on

    • Growth signaling
    • Apoptosis regulation
    • Epigenetic regulation
    • Protein homeostasis
    • Immune cell-directed therapeutic concepts
    Specific opportunities for research partnering include:

    • New insights into established and emerging cancer pathways/mechanisms
    • Potential new drug targets e.g. from cancer genomics or functional screens
    • Integrated cancer genome information to discover patient selection markers for novel precision medicines
    • Ways to engage the immune system to eliminate cancer cells

    If you have a research project and would like to explore opportunities to partner please contact our partnering team with more information.

    To discover our recent publications in Oncology please visit our Scientific Publication Pages.

    News Topic

Research & Development

Research & Development

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player